Effect of Tripterygium glycosides combined with belimumab on the efficacy and serum immune indices in patients with lupus nephritis
Central European Journal of Immunology · 19.03.2026
DOI: 10.5114/ceji/213651 ↗Kurz gefasst
Fachartikel in der Zeitschrift Central European Journal of Immunology, online erschienen am 19.03.2026. Verfasst von Qiong Liu und 2 weiteren Autor:innen. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Introduction
Lupus nephritis (LN) is an autoimmune disease with challenging clinical management. This study aimed to evaluate the efficacy of Tripterygium glycosides combined with belimumab in LN treatment and its effects on serum immune indices. Material and Methods In a randomized, open-label trial, 172 LN patients from Hebei General Hospital (June 2019-June 2022) were assigned to a control group (belimumab alone) or a study group (belimumab + Tripterygium glycosides). Primary outcomes included serum inflammatory factors, immunoglobulins (IgA, IgG, IgM), T lymphocyte subsets (CD4+, CD8+, CD4+/CD8+), complement C3 and C4, and renal function indices (24 h urinary protein, urinary microalbumin, urinary NAG). Secondary outcomes included Traditional Chinese Medicine Symptoms (TCMS) score, lupus activity (Systemic Lupus Erythematosus Disease Activity Index [SLEDAI]), clinical efficacy, and adverse reactions.
Results
After exclusions, 85 patients were included in the study group and 68 in the control group. Following treatment, both groups showed significant reductions in inflammatory factors, IgA, IgM, IgG, CD8+ T cells, renal function indices, TCMS score, and SLEDAI score, alongside increases in CD4+ T cells, CD4+/CD8+ ratio, and complement C3 and C4 (p < 0.05). Improvements were significantly greater in the study group (p < 0.05). The study group also showed higher clinical efficacy and fewer adverse reactions than the control group (p < 0.05).
Conclusions
Tripterygium glycosides combined with belimumab effectively improves inflammation, immune function, and renal function in LN patients, supporting its clinical application.
Zitieren
APA
Liu, Q., Ding, N., & Hu, Z. (2026). Effect of Tripterygium glycosides combined with belimumab on the efficacy and serum immune indices in patients with lupus nephritis. Central European Journal of Immunology. https://doi.org/10.5114/ceji/213651
Vancouver
Liu Q, Ding N, Hu Z. Effect of Tripterygium glycosides combined with belimumab on the efficacy and serum immune indices in patients with lupus nephritis. Central European Journal of Immunology. 2026. doi:10.5114/ceji/213651
BibTeX
@article{Liu2026,
author = {Liu, Qiong and Ding, Nan and Hu, Zhijuan},
title = {Effect of Tripterygium glycosides combined with belimumab on the efficacy and serum immune indices in patients with lupus nephritis},
journal = {Central European Journal of Immunology},
year = {2026},
doi = {10.5114/ceji/213651}
}
EUVIMED